SPAT inhibits LUAD metastasis by targeting SF1-mediated splicing

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Lung adenocarcinoma (LUAD) progression is driven by genetic alterations, but the complex interactions remain unclear.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
• Understanding novel regulatory mechanisms is crucial for developing effective LUAD therapies.

Purpose of the Study:

• To functionally characterize the novel lncRNA, SPAT (splice associated transcript), in LUAD.
• To elucidate the molecular mechanisms by which SPAT influences LUAD progression and metastasis.
• To evaluate SPAT's potential as a therapeutic target for LUAD.

Main Methods:

• In vitro and in vivo experimental models of LUAD.
• Analysis of SPAT expression levels and correlation with patient prognosis.
• Investigation of SPAT's interaction with splicing factor 1 (SF1).
• Assessment of KITLG/SCF splicing alterations and ERK phosphorylation.

Main Results:

• SPAT is downregulated in LUAD, with lower expression correlating with poorer prognosis.
• SPAT significantly inhibits LUAD cell migration in vitro and in vivo.
• SPAT interacts with SF1, disrupting the splicing of KITLG/SCF exon 6.
• This disruption leads to altered KITLG isoform production and reduced ERK phosphorylation.

Conclusions:

• SPAT functions as a tumor suppressor in LUAD by modulating alternative splicing.
• SPAT's mechanism involves regulating SF1-mediated splicing of KITLG/SCF, impacting the ERK pathway.
• SPAT represents a promising therapeutic target for inhibiting LUAD metastasis.